Executive leadership at Bone Biologics.
Board of directors at Bone Biologics.
Research analysts covering Bone Biologics.
Recent press releases and 8-K filings for BBLG.
Bone Biologics Highlights 2025 Milestones and Provides 2026 Outlook
BBLG
Guidance Update
New Projects/Investments
Delisting/Listing Issues
- Bone Biologics strengthened its capital position by completing a registered public offering for total gross proceeds of $5 million during the second quarter of 2025.
- The company regained compliance with Nasdaq's minimum bid price requirement in June 2025.
- In December 2025, Bone Biologics successfully extended the validated shelf life of its rhNELL-1 protein product candidate to 24 months.
- For 2026, the company plans to continue advancing its NB1 clinical program, including the expected completion of patient enrollment in its first-in-human clinical trial.
Jan 8, 2026, 1:05 PM
Bone Biologics Summarizes 2025 Milestones and Outlines 2026 Outlook
BBLG
Guidance Update
New Projects/Investments
Delisting/Listing Issues
- Bone Biologics extended the validated shelf life of its rhNELL-1 protein to 24 months and completed a registered public offering for $5 million in gross proceeds during the second quarter of 2025.
- The company also expanded its intellectual property portfolio and regained compliance with Nasdaq's minimum bid price requirement in June 2025.
- For 2026, Bone Biologics plans to continue advancing its NB1 clinical development program, including the expected completion of patient enrollment in its first-in-human clinical trial.
Jan 8, 2026, 1:00 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more